Ca2+ selectivity and fatty acid specificity of the noncapacitative, arachidonate-regulated Ca2+ (ARC) channels.
The arachidonate-regulated, Ca(2+)-selective ARC channels represent a novel receptor-activated pathway for the entry of Ca(2+) in nonexcitable cells that is entirely separate from the widely studied store-operated, Ca(2+) release-activated Ca(2+) channels. Activation of ARC channels occurs specifically at the low agonist concentrations typically associated with oscillatory Ca(2+) signals and appears to provide the predominant mode of Ca(2+) entry under these conditions (Mignen, O., Thompson, J. L., and Shuttleworth, T. J. (2001) J. Biol. Chem. 276, 35676-35683). In this study we demonstrate that ARC channels are present in a variety of different cell types including both cell lines and primary cells. Examination of their pharmacology revealed that currents through these channels are significantly inhibited by low concentrations (< 5 microm) of Gd(3+), are unaffected by 100 microm 2-aminoethyoxydiphenyl borane, and are not activated by the diacylglycerol analogue 1-oleoyl-2-acetyl-sn-glycerol (100 microm). Their selectivity for Ca(2+) was assessed by determining the EC(50) for external Ca(2+) block of the monovalent currents observed in the absence of external divalent cations. The value obtained (150 nm) indicates that the Ca(2+) selectivity of ARC channels is extremely high. Examination of the ability of various fatty acids, including arachidonic acid, to activate the ARC channels demonstrated that activation does not reflect any nonspecific membrane fluidity or detergent effects, shows a high degree of specificity for arachidonic acid over other fatty acids (especially monounsaturated and saturated fatty acids), and is independent of any arachidonic acid metabolite. Moreover, studies using the charged analogue arachidonyl coenzyme A demonstrate that activation of the ARC channels reflects an action of the fatty acid specifically at the internal face of the plasma membrane. Whether this involves a direct action of arachidonic acid on the channel protein itself or an action on some intermediary molecule is, at present, unclear.
Mignen
Olivier
O
Department of Pharmacology and Physiology, University of Rochester Medical Center, New York 14642, USA.
Thompson
Jill L
JL
Shuttleworth
Trevor J
TJ
D016718:Arachidonic Acid / Q000494:pharmacology*; D001896:Boron Compounds / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism* / Q000494:pharmacology*; D015220:Calcium Channels / Q000032:analysis / Q000187:drug effects* / Q000502:physiology; D002478:Cells, Cultured; D004075:Diglycerides / Q000494:pharmacology; D005227:Fatty Acids / Q000494:pharmacology*; D005682:Gadolinium / Q000494:pharmacology; D006801:Humans; D008274:Magnesium / Q000494:pharmacology; D008560:Membrane Fluidity / Q000187:drug effects
D001896:Boron Compounds; D015220:Calcium Channels; D004075:Diglycerides; D005227:Fatty Acids; D016718:Arachidonic Acid; C038237:1-oleoyl-2-acetylglycerol; D005682:Gadolinium; C109986:2-aminoethoxydiphenyl borate; D008274:Magnesium; D002118:Calcium